Genentech Articles
Stock Commentary - New York
10 June 2002
Genentech promotes Hal Barron
3 June 2002
Herceptin disappoints in lung cancer
3 June 2002
Genentech licenses IGF-1 rights to Tercica
27 May 2002
Avastim raises antiangiogenesis hopes
27 May 2002
InterMune acquires Amgen patent estate
20 May 2002
Genentech licenses Xenova immune technology
29 April 2002
Genentech signs deal with Seattle Genetics
29 April 2002
FDA clears Nutropin AQ Pen
29 April 2002
Immunex 1st-qtr revenues rose 25%
29 April 2002
IDEC results driven by Rituxan
29 April 2002
Stock Commentary - New York
22 April 2002
Genentech 1st-qtr earnings leap
22 April 2002
Stock Commentary - New York
15 April 2002
40% growth for IDEC/Genentech
15 April 2002
Increased pressure in biotech for future profit
15 April 2002
Update: Alkermes to acquire Reliant in $934M deal
1 April 2002
Dynavax to test ISS drug plus Rituxan in NHL
1 April 2002
Alkermes to acquire Reliant in $934M deal
25 March 2002
Seattle licenses more MAbs from Mabtech
25 March 2002
Stock Commentary - New York
4 March 2002
Actelion notes good start for Tracleer
4 March 2002
Genentech signs brain cancer pact
4 March 2002
Enbrel also active in psoriasis, says study
4 March 2002
Genta starts trial of Genasense plus Rituxan
25 February 2002
Affymax recruits chief executive.
11 February 2002
Actelion's Tracleer misses mark in chronic heart failure trial
11 February 2002
Genentech appointment
4 February 2002
AstrAZeneca files Iressa for NSCLC in Japan
4 February 2002
Fujisawa approval to import Vysis to Japan
28 January 2002
Genentech full-year 2001 revenues increase 28%
28 January 2002
IDEC/Genentech collaboration on Rituxan achieves $779M sales
28 January 2002
Seattle antibody enters development at Genentech.
21 January 2002
4SC and Wilex forge oncology collaboration.
21 January 2002
Genentech expects quiet 2002
14 January 2002
Concerns over ImClone's Erbitux deepen
14 January 2002
Celltech and Genentech settle patent dispute
7 January 2002
Celltech and Genentech settle patent dispute
19 December 2001
Test backed to screen patients for Herceptin
6 December 2001
OSI acquires oncology assets from Gilead in $200 million deal
27 November 2001
Actelion income up 153% at Q3
15 November 2001
Genentech's $625 million buyback
9 November 2001
Xolair amendment to be filed next year
2 November 2001
Stock Commentary - New York
1 November 2001
Genentech boosted by Avastin study
26 October 2001
OSI starts additional trials of anti-EGFr drug
25 October 2001
Stock Commentary - New York
25 October 2001
Stock Commentary - New York
18 October 2001
Genentech third-qtr revenues jump 24%
16 October 2001
Amevive out in front amongst new biologicals for psoriasis
16 October 2001
IDEC Pharma says 3rd qtr sales of Rituxan reach $205 million
15 October 2001
Genentech third-qtr revenues jump 24%
12 October 2001
Stock Commentary - New York
11 October 2001
Antisoma: strong fundamentals belie near-term financing troubles
10 October 2001
Xanelim delay hits Xoma and partner Genentech, boosts Biogen
8 October 2001
Genentech/Xoma delay US Xanelim submission
5 October 2001
Oncologist slams Australian PBAC
28 September 2001
Global pulmonary drug delivery market forecasts
24 September 2001
InterMune switches Actimmune production
20 September 2001
Roche's MabThera launched in Japan
14 September 2001
IDEC's Zevalin set for US approval for NHL
12 September 2001
Genentech earnings set to grow 25%
11 September 2001
New use for alteplase cleared in USA
5 September 2001
ASSENT 3 trial shows new regimen benefit
24 August 2001
Rival firms face FDA panel for PAH drugs
10 August 2001
Biogen completes US and EU filing for Amevive
8 August 2001
Tanox to consolidate research centers
31 July 2001
Actelion downgraded by Julius Baer
26 July 2001
Update: Zelmac launch, Zomaril problems at Novartis
25 July 2001
Novartis launches Zelmac in 1st market
24 July 2001
Stock Commentary - Tokyo
19 July 2001
Stock Commentary - New York
12 July 2001
Stock Commentary - Europe
12 July 2001
Net income increases 28% at Genentech
12 July 2001
XOMA completes $43 million common share financing
28 June 2001
Inspire hit as partner Genentech drops drug
25 June 2001
Roche's MabThera approved in Japan
21 June 2001
Biogen to apply for approval of Amevive
15 June 2001
Schwarz sells back hormone rights
8 June 2001
US FDA probes counterfeit drugs
5 June 2001
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
